GLAUKOS Corp 4

Director Marc Stapley received an amended-reported grant of 2,987 Glaukos Corp stock options at a corrected exercise price of $106.52 per share as routine director compensation.

On May 28, 2026, director Marc Stapley received a grant of 2,987 stock options of Glaukos Corp under the issuer’s Director Compensation Policy, with an exercise price of $106.52 and vesting in full on the one-year anniversary of the grant date; this Form 4/A is an amendment correcting the originally misreported option exercise price (previously shown as $53.57) and reflects a routine equity compensation award rather than an open-market transaction, leaving his direct beneficial ownership at 2,987 common shares subject to option. Using the current share price of approximately $134.65, the intrinsic in-the-money value of the option grant as of the snapshot date is about $84,000, and the estimated market value of the underlying shares if exercised and held would be around $402,000, highlighting standard but meaningful director equity alignment with shareholders.

Filing Facts

CIK

1192448

Ticker

GKOS

Form

4

Source Type

fda

Accession

0001539796-26-000017

Alert Tier

5